
BIOGRAPHICAL SKETCH

NAME: Trudeau, Louis-Eric

POSITION TITLE: Professor

EDUCATION/TRAINING:

INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Concordia University, Montréal	B.Sc.	1990	Psychology
Université de Paris VI	D.E.A.	1991	Neuroscience
Université de Montréal	Ph.D.	1994	Neuroscience
Iowa State University	Postdoc	1997	Neuroscience

SECTION A: Positions and honors:

Positions:

1997-2002	Assistant professor, Department of Pharmacology, Université de Montréal
2002-2008	Associate professor, Department of Pharmacology, Université de Montréal
2006:	Visiting professor, University of California, Irvine
2008-	Professor, Department of Pharmacology and Physiology, Department of neurosciences, Université de Montréal
2015:	Visiting professor, University of Amsterdam

Advisory committees and other appointments:

2000-2004	Co-director, Schizophrenia Axis, FRSQ Mental Health Network
2002-2005	Internal member, CIHR Neuroscience B evaluation committee
2004-2009	Treasurer, Canadian Association for Neuroscience
2008-2014	Internal member, CFI grants committee, FRQS
2009-2012	Treasurer, Society for Neuroscience, Montreal Chapter
2009-present	Scientific Advisory Board, Parkinson Society Canada
2012-2013	Internal review committee member, Michael J Fox Foundation
2014-2018	Internal member, CIHR Cell Physiology evaluation committee
2019-present	Director, CNS Research Group (GRSNC), Université de Montréal
2021-present	Co-director, UdeM Brain and Mental Health Initiative

Honors:

1990	J.W. Bridges medal awarded to the best graduating student in psychology, Concordia University
1990	Prize for the best graduating student of Concordia University, Science College
1990-1993	Science and Engineering "1967" graduate studies scholarship of the Natural Sciences and Engineering Research Council of Canada
1994-1996	Postdoctoral Fellowship from the Human Frontier Science Program (Long-term fellowship)
1995	Gold medal of the Governor General of Canada for the best Ph.D. thesis at Université de Montréal (1994-1995)
1997-2001	"Michael Smith" Scholar of the Medical Research Council of Canada.
1998-2000	EJLB Foundation Scholar.

2001-2003	NARSAD Young Investigator Award
2002-2005	Scholar (J-II level) of the Fonds de la Recherche en Santé du Québec.
2004	Bristol-Myers-Squibb Young Investigator Award, Canadian College of Neuropsychopharmacology
2004-2006	NARSAD Independent Investigator Award
2005-2009	Scholar (senior level) of the Fonds de la Recherche en Santé du Québec

SECTION B: Selected peer-reviewed publications (<i>last 3 years, plus a few other representative, out of a total of 117</i>)

1. Mendez, J.A., Bourque, M.-J., Bourdeau, M.L., Danik, M., Williams, S., Lacaille, J.-C., **Trudeau, L.-E.** (2008) Developmental and contact-dependent regulation of vesicular glutamate transporter expression in dopamine neurons. *Journal of Neuroscience*, 28(25): 6309-6318.
2. Birgner C, Nordenankar K, Lundblad M, Mendez JA, Smith C, le Grevès M, Galter D, Olson L, Fredriksson A, **Trudeau L.-E**, Kullander K, Wallén-Mackenzie A. (2010) VGLUT2 in dopamine neurons is required for psychostimulant-induced behavioral activation. *Proc Natl Acad Sci U S A*. 107(1):389-94.
3. El Mestikawy, S., Wallen-Mackenzie, A., Fortin, G., Descarries, L., **Trudeau, L.-E.** (2011) From glutamate corelease to vesicular synergy: new perspectives on the functions of vesicular glutamate transporters. *Nature Reviews Neuroscience* 12(4):204-16.
4. Alsö J, Nordenankar K, Arvidsson E, Birgner C, Mahmoudi S, Halbout B, Smith C, Fortin GM, Olson L, Descarries L, **Trudeau L-E**, Kullander K, Lévesque D, Wallén-Mackenzie A. (2011) Enhanced Sucrose and Cocaine Self-Administration and Cue-Induced Drug Seeking after Loss of VGLUT2 in Midbrain Dopamine Neurons in Mice. *Journal of Neuroscience* 31(35):12593-12603.
5. Fortin GM, Bourque MJ, Mendez JA, Leo D, Nordenankar K, Birgner C, Arvidsson E, Rymar VV, Bérubé-Carière N, Claveau AN, Descarries L, Sadikot AF, Wallen-Mackenzie A, **Trudeau L-E.** (2012) Glutamate corelease promotes growth and survival of midbrain dopamine neurons. *Journal of Neuroscience*, 32(48) : 17447-17492.
6. Sanchez G., Varaschin RK, Bueler H, Marcogliese PC, Park DS, **Trudeau L-E** (2014) Unimpaired striatal dopamine release in juvenile Parkin knockout, Pink1 knockout, DJ-1 knockout and LRRK2 R1441G transgenic mice *PloS One* 9(4): e94826.
7. Pacelli C, Giguère N, Bourque MJ, Lévesque M, Slack RS, **Trudeau L-É.** (2015) Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons. *Current Biology* 25(18):2349-60.
8. Matheoud D, Sugiura A, Bellemare-Pelletier A, Laplante A, Rondeau C, Chemali M, Fazel A, Bergeron JJ, **Trudeau L-E**, Burelle Y, Gagnon E, McBride HM, **Desjardins M.** (2016) Parkinson's Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation. *Cell* 166(2):314-27.
9. Doucet-Beaupré H, Gilbert C, Profes MS, Chabrat A, Pacelli C, Giguère N, Rioux V, Charest J, Deng Q, Laguna A, Ericson J, Perlmann T, Ang SL, Cicchetti F, Parent M, **Trudeau L-E**, Lévesque M. (2016) Lmx1a and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons. *Proc Natl Acad Sci U S A* 113(30):E4387-96
10. Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JHM, Najarali Z, Khan MH, Thiele SL, Semmen MS, Koprach JB, Brotchie JM, Eubanks JH, **Trudeau L-E**, Nash JE (2017) Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α -synuclein rat model of parkinsonism. *Neurobiology of Disease* 106:133-146.
11. Hryhorczuk C, Sheng Z, Décarie-Spain L, Giguère N, Ducrot C, **Trudeau L-E**, Routh V, Alquier T, Fulton S (2018) Oleic acid in the ventral tegmental area inhibits feeding, food reward and dopamine tone. *Neuropsychopharmacology* 43(3):607-616.
12. Koerich Varaschin R, Osterstock G, Ducrot C, Leino S, Bourque M-J, Prado MAM, Prado VA, Salminen O, Rannanpää S, **Trudeau L-E** (2018) Histamine H3 receptors decrease release in the

- ventral striatum by reducing the activity of striatal cholinergic interneurons. *Neuroscience*, 376:188-203.
13. Giguère N, Pacelli C, Saumure C, Bourque M-J, Matheoud D, Lévesque D, Slack RS, Park D, **Trudeau L-E** (2018) Comparative analysis of Parkinson's disease-associated genes in mice reveals altered survival and bioenergetics of Parkin deficient dopamine neurons. *Journal of Biological Chemistry* 293(25):9580-9593.
 14. Giguère N, Burke Nanni S, **Trudeau LE**. (2018) On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease. *Frontiers in Neurology* Jun 19;9:455.
 15. **Trudeau LE**, El Mestikawy S. (2018) Glutamate Cotransmission in Cholinergic, GABAergic and Monoamine Systems: Contrasts and Commonalities. *Frontiers in Neural Circuits*. 18;12:113.
 16. Fortin GM, Ducrot C, Giguère N, Kouwenhoven W, Bourque M-J, Pacelli C, Varaschin RK, Brill M, Singh S, Wiseman PW, **Trudeau L-E** (2019) Segregation of dopamine and glutamate release sites in dopamine neuron axons: regulation by striatal target cells. *FASEB Journal* 33(1):400-417.
 17. Zhu H, Lussier F, Ducrot C, Bourque MJ, Spatz JP, Cui W, Yu L, Peng W, **Trudeau LE**, Bazuin CG, Masson JF. (2019) Block copolymer brush layer-templated gold nanoparticles on nanofibers for surface-enhanced Raman scattering optophysiology. *ACS Appl Mater Interfaces*. 11(4):4373-4384.
 18. Apergis-Schoute J, Burnstock G, Nusbaum MP, Parker D, Morales MA, **Trudeau L-E**, Svensson E (2019) Editorial: Neuronal Co-transmission, *Frontiers in Neural Circuits* 13:19.
 19. Matheoud D, Cannon T, Voisin V, Penttinen A-M, Ramet L, Fahmy AM, Ducrot C, Laplante A, Bourque M-J, Zhu L, Cayrol R, Le Campion A, McBride HM*, Gruenheid S*, **Trudeau L-E***, Desjardins M* (2019) Intestinal infection triggers Parkinson's disease-like symptoms in Pink1-/- mice. *Nature*, 571(7766):565-569 (* co-corresponding authors)
 20. Giguère N, Delignat-Lavaud B, Herborg F, Voisin A, Li Y, Jacquemet V, Anand-Srivastava M, Gether U, Giros B, **Trudeau LÉ**. (2019) Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout. *PLoS Genetics*, 15(8):e1008352
 21. Wong Y, Luk K, Purtell K, Burke Nanni S, Stoessl AJ, **Trudeau LE**, Yue Z, Krainc D, Oertel W, Obeso JA, Volpicelli-Daley L (2019) Neuronal Vulnerability in Parkinson Disease and Putative Therapeutics: Should the focus be on axonal and synaptic terminals? *Movement Disorders*, 34(10): 1406-1422.
 22. Anilkumar U, Khacho M, Cuillerier A, Harris R, Patten DA, Bilen M, Iqbal MA, Guo DY, **Trudeau LE**, Park DS, Harper ME, Burelle Y, Slack RS. (2020) MCL-1 Matrix maintains neuronal survival by enhancing mitochondrial integrity and bioenergetic capacity under stress conditions. *Cell Death and Disease*, 11(5):321.
 23. Wallace G, Delignat-Lavaud B, Zhao X, **Trudeau LE**, Masson JF (2020) A Blueprint for Performing SERS Measurements in Tissue with Plasmonic Nanofibers. *Journal of Chemical Physics* 153(12):124702.
 24. Allain F, Delignat-Lavaud B, Beaudoin MP, Jacquemet V, Robinson TE, **Trudeau LE**, Samaha AN. (2020) Amphetamine maintenance therapy during intermittent cocaine self-administration in rats attenuates psychomotor and dopamine sensitization and reduces addiction-like behavior. *Neuropsychopharmacology*;46(2):305-315.
 25. Kouwenhoven WM, Fortin G, Penttinen AM, Florence C, Delignat-Lavaud B, Bourque MJ, Trimbuch T, Luppi MP, Salvail-Lacoste A, Legault P, Poulin JF, Rosenmund C, Awatramani R, **Trudeau LÉ**. (2020) VGluT2 Expression in Dopamine Neurons Contributes to Postlesional Striatal Reinnervation. *Journal of Neuroscience* 40(43):8262-8275.
 26. Cannon T, Sinha A, **Trudeau LE**, Maurice CF, Gruenheid S (2020) Characterization of the intestinal microbiota during *Citrobacter rodentium* infection in a mouse model of infection-triggered Parkinson's disease. *Gut Microbes* 12(1):1-11.
 27. Ducrot C, Bourque MJ, Delmas CVL, Racine AS, Guadarrama Bello D, Delignat-Lavaud B, Lycas MD, Fallon A, Michaud-Tardif C, Burke Nanni S, Herborg F, Gether U, Nanci A, Takahashi H, Parent M, **Trudeau L-E** (2021) Dopaminergic neurons establish a distinctive axonal arbor with a

- majority of non-synaptic terminals. *FASEB Journal*, Aug;35(8):e21791. doi: 10.1096/fj.202100201RR.
28. Tanguay W, Ducrot C, Giguère N, Bourque MJ, **Trudeau L-E**. (2021) Neonatal 6-OHDA lesion of the SNc induces striatal compensatory sprouting from surviving SNc dopaminergic neurons without VTA contribution. *European Journal of Neuroscience* Oct;54(7):6618-6632. doi: 10.1111/ejn.15437.
 29. Delignat-Lavaud B, Ducrot C, Kouwenhoven W, Feller N, **Trudeau L-E** (2022) Implication of synaptotagmins 4 and 7 in activity-dependent somatodendritic dopamine release. *Open Biology*, Mar;12(3):210339. doi: 10.1098/rsob.210339. Epub 2022 Mar 2.
 30. Delignat-Lavaud B, Kano J, Ducrot C, Massé I, Mukherjee S, Giguère N, Moquin L, Lévesque C, Burke S, Bourque M-J, Rosa-Neto P, Lévesque D, De Beaumont L, **Trudeau L-E** (2022) The calcium sensor synaptotagmin-1 is critical for phasic axonal dopamine release in the striatum and mesencephalon, but is dispensable for basic motor behaviors in mice. *Nature Communications*, revisions requested. *BioRxiv* doi: <https://doi.org/10.1101/2021.09.15.460511>.